The short answer
The 2026 obesity pipeline splits along two axes: how many receptors a molecule engages, and how it is administered. Retatrutide leads on magnitude as a triple agonist, CagriSema and amycretin add amylin to GLP-1, survodutide and mazdutide add glucagon, and orforglipron is the first non-peptide taken as a tablet.
Key facts
- Largest reported reduction
- Retatrutide: 28.3% at 80 weeks
- First non-peptide approved
- Orforglipron: MHRA, 10 Aug 2026
- Amylin + GLP-1
- CagriSema, amycretin
- Glucagon-containing
- Retatrutide, survodutide, mazdutide
- Approved in China
- Mazdutide
- Highest oral Phase 2
- Aleniglipron: 15.3% at 44 weeks
- Common limitation
- Gastrointestinal tolerability across all
The two axes that organise the field
Almost every compound in development can be placed by answering two questions. How many receptors does it engage: one, two or three? And is it a peptide, which generally means injection, or a small molecule, which can be a tablet? Adding receptors has consistently increased effect size and consistently increased gastrointestinal burden. The oral trade-off looked equally consistent until 2026: orforglipron reported 11.2% where injectable multi-agonists report twice that. Aleniglipron has complicated it, reporting 15.3% absolute at 44 weeks in Phase 2, still short of retatrutide but no longer in a different league. The gap between routes now looks narrower than the gap between one receptor and three.
Triple agonists: retatrutide
Retatrutide engages GIP, GLP-1 and glucagon receptors from a single 39-residue peptide. TRIUMPH-1 reported mean reduction of 28.3% at 80 weeks on 12 mg, the largest figure yet reported for a single molecule, with a 104-week extension reaching 30.3% in participants with baseline BMI of 35 or above. It remains investigational everywhere; an FDA filing was signalled for Q1 2027.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Amylin combinations: CagriSema and amycretin
Amylin is a separate satiety hormone co-secreted with insulin, and combining amylin agonism with GLP-1 agonism is the other main strategy for increasing effect size. CagriSema is a fixed-dose combination of cagrilintide and semaglutide, both at 2.4 mg once weekly. Amycretin takes the harder route, engaging both GLP-1 and amylin receptors from one molecule, and exists in both weekly subcutaneous and daily oral forms.
Glucagon-containing dual agonists: survodutide and mazdutide
Adding glucagon-receptor activity raises energy expenditure and has a particular effect on hepatic fat, which is why survodutide has been pursued in metabolic liver disease alongside obesity. Mazdutide, a GLP-1/glucagon dual agonist developed by Innovent with Eli Lilly, is approved in China but not in the United States or European Union, and reported roughly 20% reduction on 9 mg in Chinese Phase 3 work.
The oral route: orforglipron
Orforglipron is the outlier because it is not a peptide at all. It reached 11.2% mean reduction at 72 weeks on its highest dose. That is well below the injectable multi-agonists, but it is an ordinary tablet with no absorption enhancer, no fasting window and conventional manufacturing economics. The MHRA authorised it on 10 August 2026, the first such approval in Europe. Aleniglipron, a second oral non-peptide from Structure Therapeutics, has since reported substantially higher Phase 2 figures (15.3% absolute at 44 weeks on 180 mg, with no plateau reached), which suggests orforglipron's effect size reflects that molecule rather than a ceiling on the oral route.
What everything in the pipeline still shares
Gastrointestinal adverse events dominate across every compound and every mechanism, and discontinuation rates rise with dose in all of them. Weight regain after cessation is unresolved across the entire class. Adding receptors has not solved either problem, and neither has changing route.
Quick reference
| Compound | Receptors | Route | Reported reduction | Status |
|---|---|---|---|---|
| Retatrutide | GIP/GLP-1/glucagon | Weekly injection | 28.3% @ 80 wks | Investigational |
| CagriSema | Amylin + GLP-1 | Weekly injection | 22.7% @ 68 wks | Filed / under review |
| Amycretin | GLP-1 + amylin | Weekly SC or daily oral | Up to 14.5% @ 36 wks | Entering Phase 3 |
| Mazdutide | GLP-1/glucagon | Weekly injection | ~20% (9 mg, Ph3) | Approved in China |
| Survodutide | GLP-1/glucagon | Weekly injection | Phase 3 reported | Investigational |
| Orforglipron | GLP-1 only | Daily tablet | 11.2% @ 72 wks | Authorised (UK) |
| Aleniglipron | GLP-1 only | Daily tablet | 15.3% @ 44 wks (Ph2) | Investigational |
Frequently asked questions
Which compound produces the largest reduction?
Retatrutide, on the figures reported so far: 28.3% at 80 weeks in TRIUMPH-1. It is also still investigational, so that number comes from trials rather than clinical use.
Why does the tablet lose less weight?
Because orforglipron engages only the GLP-1 receptor. The larger figures come from molecules adding GIP, glucagon or amylin, and no small molecule has yet achieved that. Route matters less than receptor count. Aleniglipron is also an oral single-receptor agonist and reported 15.3% in Phase 2.
Are any of these available in the UK?
Orforglipron is authorised as Foundayo. The rest are investigational or, in mazdutide's case, approved only in China.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- RefTRIUMPH-1 topline results: Eli Lillyinvestor.lilly.com
- RefCagriSema REDEFINE 1: published in NEJMprnewswire.com
- RefAmycretin Phase 2 in type 2 diabetes. Novo Nordisknovonordisk.com
- RefOrforglipron: A Comprehensive Review. Int J Mol Sci 2026mdpi.com
- RefAleniglipron ACCESS II topline. Structure Therapeuticsir.structuretx.com
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- What Is CagriSema? Cagrilintide Plus SemaglutideCagriSema combines cagrilintide and semaglutide at 2.4 mg each. REDEFINE 1 reported 22.7% mean reduction at 68 weeks - and 20.4% on the other estimand.
- What Is Amycretin? One Molecule, Two ReceptorsAmycretin is a unimolecular GLP-1 and amylin receptor agonist from Novo Nordisk, in weekly injectable and daily oral forms. Phase 2 data and trial design.
- What Is an Amylin Receptor Agonist?Amylin is a 37-residue hormone co-secreted with insulin. How amylin receptor agonists signal satiety through the area postrema, and why they pair with GLP-1.
- Glucagon-Containing Dual Agonists: Survodutide and MazdutideWhy adding glucagon-receptor activity raises energy expenditure and targets liver fat. Survodutide and mazdutide trial status, and the counterintuitive logic.
- What the Data Says About Weight Regain After StoppingSTEP-1 extension found about two-thirds of lost weight returned within a year of stopping semaglutide. Meta-analyses put regain at roughly 0.8 kg per month.